• New approaches to the treatment of an acute respiratory viral infections among children
To content

New approaches to the treatment of an acute respiratory viral infections among children

SOVREMENNAYA PEDIATRIYA.2014.4(60):111115; doi 10.15574/SP.2014.60.111 

New approaches to the treatment of an acute respiratory viral infections among children

Gerasimov S. V., Belova G. A., Pavuk G. L., Senyuk I. M., Strekalina Y. I., Zapok A. A. 
Municipal state polyclinic № 4, Lviv, Ukraine 
Lviv national medical university named after Danylo Galitsky, Ukraine

Purpose: to study the effectiveness of the Erebra drug (dry extract of the sea buckthorn leaves) in an acute respiratory viral infection (ARVI) among the preschool and primary school age children.

Patients and methods: there were observed 43 children with ARVI of the 3–12 years who were divided in two groups. All the patients were appointed the symptomatic treatment, the main group of children got the Erebra drug according to their age dosage.

Results: during the drug use the duration of rhinorrhea was decreased for two days, sneezing, nasal congestion and for three days — the sore throat. Duration of the very symptoms such as cephalalgia, myalgia, hoarseness, coughing were practically unchanged.

Conclusions: the Erebra drug can be considered as an effective ARVI treatment among the preschool and the primary school age children.

Key words: an acute respiratory viral infection, children, Erebra.

REFERENCES 
1. Бортникова ВВ. 2011. Экспериментальное изучение безопасности гипорамина — нового фитопрепарата противовирусного действия. Биомедицина. 3: 106—108.

2. Вичканова СА, Крутикова НМ. 2000. Особенности клинической эффективности гипорамина при вирусных инфекциях. Химия, технология, медицина. Сб тр ВИЛАР. М: 240—249.

3. Вичканова СА, Шипулина ЛД, Толкачев ОН, Фадеева ТВ, Шейченко ОП, Белошапко АА, Храпцев ЕЕ, Баринский ИФ, Нестерчук СЛ, Фадеева НИ, Герасина СФ. Биологически активное вещество против вируса СПИД. Патент на изобретение №1805967 с приор. 3.11.87 г. Заявка № 4335127. Зарег. в Гос. реестре изобр. 9.10.92 г.

4. Шипулина ЛД, Носач ЛН, Бутенко СИ и др. 1998. Изучение гипорамина на респродукцию аденовируса в культуре клеток. Человек и лекарство. Тез докл V Рос нац конгр. М: 639.

5. Шипулина ЛД, Толкачев ОН, Шейченко ОП и др. 1997. Корреляционный анализ противовирусных агентов: гидролизируемых танинов облепихи крушиновидной. Человек и лекарство. Тез докл IV Росс нац конгр. М: 239.

6. Шипулина ЛД, Ленева ИА, Федякина ИТ. 2000. Экспериментальное изучение активности гипорамина методом иммуноферментного анализа в отношении респираторно-синцитиального вируса. Химия, технология, медицина. Сб тр ВИЛАР. М: 258—262.

7. Вичканова СА, Крутикова НМ, Вартанян РВ и др. 2000. Эффективность гипорамина при вирусных инфекциях у детей. Тез докл VII Рос нац конгр «Человек и лекарство», Москва, 10—14 апр. 2000 г. М: 208.

8. Upadhyay NK, Kumar MSY, Gupta A. 2010. Antioxidant, cytoprotective and antibacterial effects of Sea buckthorn (Hippophae rhamnoides L.) leaves. Food and Chemical Toxicology. 48: 3443—3448.

9. Shipulina LD, Tolkachev ON, Krepkova LV et al. 2005.Anti-viral anti-microbial and toxicological studies on Seabuckthorn (Hippophae rhamnoides). A Multipurpose Wonder Plant. Singh V (Ed), Seabuckthorn (Hippophae L). 2. New Delhi, India, Daya Publishing House: 471—483.

10. Cox DR. 1972. Regression models and life-tables. J R Stat Soc B: 187—220.

11. Sauro A, Barone F, Blasio G et al. 2006. Do influenza and acute respiratory infective diseases weigh heavily on general practitioners' daily practice? Eur J Gen Pract. 12: 34—36.

12. Ehlken B, Ihorst G, Lippert B et al. 2005. Economic impact of community_acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr. 164: 607—615.

13. Taylor JA, Weber W, Standish L et al. 2003. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA. 290: 2824—2830.

14. Fashner J, Ericson K, Werner S. 2012. Treatment of the common cold in children and adults. Am Fam Physician. 86(2): 153—159.

15. Haskins R, Kotch J. 1986. Day care and illness: evidence, costs and public policy. Pediatrics. 77: 951—982.

16. http://www.moz.gov.ua/ua/portal/dn_20071210_803.html

17. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53: 457—486.

18. Kirkwood BR, Sterne JAC. 2004. Medical statistics. Malden, Blackwell Science: 152—153.

19. Kusel MM, de Klerk N, Holt PG et al. 2007. Occurrence and management of acute respiratory illnesses in early childhood. J Paediatr Child Health. 43: 139—146.

20. Olszewska W, Zambon M, Openshaw PJM. 2002. Development of vaccines against common colds. Br Med Bull. 62: 99—111.

21. Jefferson T, Jones M, Doshi P et al. 2014. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 9: 348:g2545. http://dx.doi.org/10.1136/bmj.g2545.

22. Nicholson KG, McNally T, Silverman M et al. 2006. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine. 24: 102—108.

23. Massin MM, Montesanti J, Gerard P, Lepage P. 2006. Spectrum and frequency of illness presenting to a pediatric emergency department. Acta Clin Belg. 61: 161—165.

24. Lambert SB, Allen KM, Carter RC, Nolan TM. 2008. The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children. Respir Res. 9: 11. doi:10.1186/1465—9921—9—11.

25. Mitra A, Hannay D, Kapur A, Baxter G. 2011. The natural history of acute upper respiratory tract infections in children. Prim Health Care Res Dev. 12: 329—334.

26. Chonmaitree T, Revai K, Grady JJ et al. 2008. Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis. 46: 815—823.